Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Maya Jeje Schuang Lü, Urup, T., Gillberg, L., Kaastrup, K., Lü, M., Michaelsen, S., Larsen, V., Christensen, I., Broholm, H., Lassen, U., Grønbæk, K., Poulsen, H. (2020), Mol Oncol. doi: 10.1002/1878-0261.12660